This technology involves a whitening cosmetic composition containing solvent extracts and fractions of the halophyte Atriplex gmelini, obtained using ethanol or aqueous ethanol. The same extract is also utilized in pharmaceutical compositions for the prevention and treatment of hyperpigmentation disorders and in whitening quasi-drugs.
Skin tone, dark spots, and blemishes are largely determined by melanin pigment, which is produced when enzymes like tyrosinase oxidize and polymerize tyrosine in melanocytes. Factors such as genetics, hormones, stress, and UV exposure accelerate pigment formation. Existing whitening agents often have limited inhibitory effects or safety concerns, creating a need for safer natural alternatives.
By concentrating active ingredients through ethyl acetate or chloroform fractionation, this technology achieves a melanin inhibition effect up to three times greater than arbutin, with a formulation range of 0.0001 to 20 wt%. It can be applied to various formulations such as essences, creams, sunscreens, and foundations, as well as quasi-drugs for improving pigmentation, enabling the commercialization of domestic halophytes as high-safety whitening ingredients.
This invention was developed with support from the Ministry of Science and ICT's Fibrosis Control Research Center.
N/A
